Kangji Pharmaceutical - B (02171.HK) announced its interim results, with a net loss of 75.48 million yuan, a decrease of 78.53% compared to the same period last year.

The Zhitong Finance and Economics APP reported that Koji Pharmaceuticals -B (02171.HK) announced its mid-year performance for 2025, with revenue of 50.961 million yuan, a year-on-year increase of 703.8%; gross profit of 29.369 million yuan, a year-on-year increase of approximately 17.16 times; net loss of 75.483 million yuan, a year-on-year reduction of 78.53%; and a loss per share of 0.14 yuan.